NFE2L2 and neoplasm: Elevated NRF2 expression or KEAP1/NFE2L2 mutations are associated with advanced pathological stages, higher tumor burden, and worse prognosis in multiple cancers [5,54,55,56] as demonstrated by extensive clinical evidence, summarized in Table 1.